Last reviewed · How we verify
Nucleoside Analogs
Nucleoside analogs are synthetic molecules that mimic natural nucleosides and inhibit viral or cancer cell replication by interfering with nucleic acid synthesis.
Nucleoside analogs are synthetic molecules that mimic natural nucleosides and inhibit viral or cancer cell replication by interfering with nucleic acid synthesis. Used for Viral infections (HIV, hepatitis B, herpes simplex virus, cytomegalovirus), Certain hematologic and solid malignancies.
At a glance
| Generic name | Nucleoside Analogs |
|---|---|
| Sponsor | Third Affiliated Hospital, Sun Yat-Sen University |
| Drug class | Nucleoside analog |
| Modality | Small molecule |
| Therapeutic area | Virology / Oncology |
| Phase | FDA-approved |
Mechanism of action
Nucleoside analogs are incorporated into viral or cellular DNA/RNA during replication, causing chain termination or introducing mutations that prevent proper nucleic acid function. They are used broadly across antiviral and anticancer therapies, with specific mechanisms depending on the particular analog and target pathogen or malignancy.
Approved indications
- Viral infections (HIV, hepatitis B, herpes simplex, cytomegalovirus)
- Hematologic malignancies and solid tumors
Common side effects
- Bone marrow suppression
- Peripheral neuropathy
- Gastrointestinal disturbances
- Hepatotoxicity
- Lactic acidosis
Key clinical trials
- Comparing the New Anti-cancer Drug Eribulin With Chemotherapy Against the Usual Chemotherapy Alone in Metastatic Urothelial Cancer (PHASE3)
- Withdrawal of Therapy After Long-Term Antiviral Treatment for Chronic Hepatitis B
- Ascorbate in Myelodysplastic Syndrome (PHASE2)
- A Study to Learn About the Study Medicine PF-07985045 When Given Alone or With Other Anti-cancer Therapies in People With Advanced Solid Tumors That Have a Change in a Gene. (PHASE1)
- 5-aza-4'-Thio-2'-Deoxycytidine (Aza-TdC) in People With Advanced Solid Tumors (PHASE1)
- Phase I Trial of 4'-Thio-2'-Deoxycytidine (TdCyd) in Patients With Advanced Solid Tumors (PHASE1)
- Efficacy of Hypomethylating Agents vs. Intensive Chemotherapy in Acute Myeloid Leukemia Using 5hmC as a Blood-Based Minimal Residual Disease Marker (PHASE2)
- Prevention of Recurrence of Herpes Simplex in Autoimmune Rheumatic Diseases (PHASE4)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Nucleoside Analogs CI brief — competitive landscape report
- Nucleoside Analogs updates RSS · CI watch RSS
- Third Affiliated Hospital, Sun Yat-Sen University portfolio CI